Despite launching with just days left in 2023, Sage Therapeutics’ postpartum depression therapy Zurzuvae made $1.6 million in sales, the Massachusetts-based biotech reported in Wednesday’ s fourth-quarter and full-year earnings results.
Tag Archive for: zuranolone
Biogen Inc. said on Tuesday it would pause or discontinue studies of some experimental drugs and therapies and focus on more promising treatments, in the latest attempt by the new chief to cut costs.
Biogen’s $1.5 billion bet is in the home stretch. On Monday, the Cambridge biotech, along with partner Sage Therapeutics, announced the FDA has accepted the New Drug Application for zuranolone and granted it priority review in two mental health indications.
Among updates from several pharma companies, Sanofi CEO Paul Hudson presented the company’s outlook for the new year, highlighting upcoming milestones and achievements that mark what he called the “new Sanofi.”
Sage Therapeutics and Biogen’s zuranolone met its primary and key secondary endpoints in the Phase III SKYLARK study of women with postpartum depression (PPD), the companies announced Monday.
